SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

BP8 Ocean Sciences Ltd

Healthcare · Drug Manufacturers - Specialty & Generic · website
$0.01
52wk 0.00 – 0.03
Overall
59.0
Value
99.7
Growth
100.0
Health
0.0
Quality
0.0
Momentum
87.7
Dividend
—
Price
About Ocean Sciences Ltd

Ocean Sciences Ltd, together with its subsidiaries, engages in sourcing, producing, marketing, and selling traditional medicines in Australia, Singapore, China, and Southeast Asia. The company's products include raw bird's nest and processed bird's nest products, and Caulerpa Lentillifera, sea grapes, and seaweeds. Its products are used in the food, nutrition, healthcare, health supplements, cosmetics and personal care industries. Ocean Sciences Ltd was formerly known as BPH Global Ltd and changed its name to Ocean Sciences Ltd in September 2026. The company was incorporated in 1984 and is based in Melbourne, Australia.

Price analytics

Returns

1 day -12.5%
1 week 7.7%
1 month 1,300.0%
3 months 833.3%
6 months 600.0%
1 year 600.0%
3 years 40.0%

Risk

Volatility (1y ann.) 954.2%
Beta vs ASX 200 1.01
Sharpe (1y) 1.36
VaR 95% (1-day) -25.0%
Max drawdown (1y) -66.7%
Off 1-year high -30.0%

Technicals

RSI(14) 48
vs 50DMA 131.4%
vs 200DMA 379.5%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 99.7
Trailing P/E
—
Forward P/E
—
PEG ratio
—
EV / EBITDA
100
Price / Book
100
Price / Sales
99
Growth 100.0
Revenue growth (1y)
100
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 0.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
0
Debt / Equity
—
Quality (Profitability & Cash Flow) 0.0
Return on equity
—
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 87.7
6-month return vs ASX 200
100
Price vs 200-day average
100
Price vs 50-day average
100
Position in 52-week range
41

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$3.06M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.53
EV / EBITDA
-1.80
Price / Book
-3.25
ROE
—
Operating margin
-37.6%
Net margin
-51.9%
Total cash
$259,882
Total debt
$555,741
Current ratio
0.59
Debt / Equity
—
Free cash flow
$-2.15M
Avg volume
122,362
Latest annual results (FY ending 30 Jun 2025)
  • Revenue—
  • Gross profit—
  • Operating income—
  • Net income—
  • Diluted EPS-0.00
  • Free cash flow—
  • Net debt—
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4